Keyphrases
Cancer Screening
20%
Clinical Benefit
20%
Clinical Costs
20%
Computed Tomography Screening
100%
Cost-benefit
20%
Cost-effectiveness
20%
Cost-effectiveness Analysis
100%
Decision Analysis
100%
Decision Cost
100%
Decision-analytic Model
40%
Derived Model
20%
End Results Program
20%
Hodgkin Lymphoma
40%
Hodgkin Lymphoma Survivors
100%
Improved Survival
20%
Incremental Cost-effectiveness Ratio
40%
Initial Diagnosis
20%
Low-dose Computed Tomography Screening
20%
Lung Cancer
20%
Lung Cancer Screening
40%
Lymphoma Patients
20%
Markov Decision
20%
Non-smokers
60%
Quality-adjusted Life Years
80%
Quality-adjusted Survival
40%
Screening for Lung Cancer
100%
Screening Strategy
20%
Smokers
80%
Stage Shift
20%
Surveillance Epidemiology
20%
Survival Benefit
20%
Medicine and Dentistry
Cancer Screening
16%
Computer Assisted Tomography
100%
Cost-Effectiveness Analysis
100%
Hodgkin's Lymphoma
100%
Low Drug Dose
16%
Lung Cancer
100%
Lung Cancer Screening
33%
Quality Adjusted Life Year
66%
Surveillance, Epidemiology, and End Results
16%